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Signaling and Regulation
CTCF and BORIS Regulate Rb2/p130 Gene Transcription:
A Novel Mechanism and a New Paradigm for Understanding
the Biology of Lung Cancer
Francesco Paolo Fiorentino1,2, Marcella Macaluso1, Fabrizio Miranda1,3, Micaela Montanari1,
Antonio Russo1,2, Luigi Bagella1,4, and Antonio Giordano1,5,6
Abstract
Although innumerable investigations regarding the biology of lung cancer have been carried out, many
aspects thereof remain to be addressed, including the role played by the retinoblastoma-related protein Rb2/
p130 during the evolution of this disease. Here we report novel findings on the mechanisms that control Rb2/
p130 gene expression in lung fibroblasts and characterize the effects of Rb2/p130 deregulation on the
proliferative features of lung cancer cells. We revealed for the first time that in lung fibroblasts the expression of
Rb2/p130 gene is directly controlled by the chromatin insulator CCCTC-binding factor, CTCF, which by
binding to the Rb2/p130 gene promoter induces, and/or maintains, a specific local chromatin organization that
in turn governs the transcriptional activity of Rb2/p130 gene. However, in lung cancer cells the activity of
CTCF in controlling Rb2/p130 gene expression is impaired by BORIS, a CTCF-paralogue, which by binding
to the Rb2/p130 gene could trigger changes in the chromatin asset established by CTCF, thereby affecting
CTCF regulatory activity on Rb2/p130 transcription. These studies not only provide essential basic insights
into the molecular mechanisms that control Rb2/p130 gene expression in lung cancer, but also offer a potential
paradigm for the actions of other activators and/or corepressors, such as CTCF and BORIS, that could be
crucial in explaining how alterations in the mechanism regulating Rb2/p130 gene expression may accelerate
the progression of lung tumors, or favor the onset of recurrence after cancer treatment. Mol Cancer Res; 9(2);
225–33. 2011 AACR.
Introduction
Lung cancer is one of the most frequent human cancers in
bothmales and females, and only 13% to 15%of lung cancer
patients survive more than 5 years (1). This inadequate
prognosis is due to lack of effective screening modalities
for lung cancer, which results in patients presenting with
advanced stage disease that is not responsive to current
therapies. Lung cancers are divided into small cell (SCLC)
and nonsmall cell (NSCLC) lung cancer depending on their
pathological and histological features and, from the stand-
point of genetic alterations SCLC and NSCLC are two
markedly different entities. Approximately 80% of lung
cancer cases are NSCLC (which includes squamous cell
carcinoma, adenocarcinoma and large cell carcinoma), and
the remaining fraction is SCLC. SCLC is the most aggressive
type of lung cancer and is defined not only by its characteristic
neuroendocrine differentiation but also by a specific set of
genetic aberrations, including the loss of the tumor suppres-
sor gene p53 (>75%) andRb1 (>90%), and the amplification
of any member of the Myc family of oncogenes (2). Onco-
genic mutations of Ras protein are exclusively found in
NSCLC tumors (3). Of interest is the specificity observed
in the mutation patterns affecting the p16INK4a/CyCD1/
RB1 pathway in NSCL and SCLC. Alteration of this path-
way is found in virtually all tumor types however, despite the
mutual exclusiveness of the mutations in these genes, altera-
tions in p16INK4a (30% to 70%),CycD1 orCDK4 are most
commonly seen inNSCLC, whereas Rb1 gene inactivation is
a typical feature of SCLC (4). This information suggests that
distinct molecular pathways might be constitutively active in
NSCLC and SCLC cells contributing to their phenotypic
differences and cellular responses to proliferation, differen-
tiation, and survival signals.
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Importantly, the diversity of these responses may be due
at least in part to a distinct activity of Rb2/p130- and p107-
retinoblastoma related proteins. Rb1, Rb2/p130, and p107
share extensive overlapping functions in cells in culture, but
they also have distinct functions in vivo (5, 6). Importantly,
it has been indicated that Rb family proteins have cell
type-specific functions in the lung epithelium important
for development and tumor suppression. Although Rb1
plays a critical unique role in regulating epithelial prolifera-
tion and survival, Rb2/p130 and p107 have distinct roles in
Rb1-deficient cells: Rb2/p130 promotes apoptosis, whereas
p107 induces cell cycle arrest (7). Furthermore, it has been
reported that Rb2/p130- and p107-deficient cells are insen-
sitive to p16-induced growth arrest, supporting a role for
these Rb1-related proteins in protecting against cancer (8).
Although innumerable investigations have been carried
out, many issues regarding the biology of lung cancer
remain to be addressed, including the role played by
Rb2/p130 and p107 during the evolution of this disease.
The contribution of Rb2/p130 to lung tumorigenesis has
been indicated by us and other investigators however, it
remains controversial and under debate. Supporting a Rb2/
p130 tumor suppressor activity there are studies showing
mutations of this gene in SCLC cell lines and primary lung
tumors, as well as studies demonstrating that the ectopic
overexpression of Rb2/p130 in lung cancer cell lines sup-
presses cell growth, and studies indicating an independent
role of Rb2/p130 expression in the development and/or
progression of human lung cancer (9, 10, 11). On the other
hand, challenging a role for Rb2/p130 in lung tumorigen-
esis, there are other studies reporting a functional Rb2/p130
expression in both lung tumor cell lines and primary
tumors, and studies reporting reduced expression of Rb2/
p130 in SCLC cell lines but absence of Rb2/p130 gene
mutation (12, 13).
Clearly, there are still insufficient and conflicting data to
understand the role played by Rb2/p130 in lung cancer and
link the altered Rb2/p130 expression observed in NSCLC
and SCLC cells with the genetic mutation of this gene.
Importantly, our studies on RB2/p130 in lung cancer
have revealed that this gene is not a "classic tumor sup-
pressor" but its activity, as a strong or weak oncosuppressor,
strongly depends on the cellular context, the tumor micro-
enviroment, and other genetic and epigenetic alterations,
such as Rb1 and p107 loss of function, Ras activation and
altered function of Rb2/p130 itself. For instance, Rb2/p130
activity could rely on specific alterations in the p16INK4a/
CyCD1/RB1 or p14 ARF/mdm2/p53 pathway in nonsmall
and small cell lung cancer. An intricate feedback loop
between Rb2/p130 activity and antiproliferative and pro-
liferative signaling (e.g., MAPK estrogen and TGF-b signal-
ing) in turn could trigger tumor suppression or tumor
progression, raising the important question of what other
cellular function(s) of Rb2/p130 are at play in lung cancer.
The chromatin insulator CCCTC-binding factor
(CTCF) is a ubiquitously expressed nuclear protein binding
approximately 20,000 sites on the human genome through
eleven DNA-binding zing finger domains (14). CTCF
possesses many DNA-regulation functions, including acting
as a chromatin insulator, enhancer blocker, transcription
activator, and nuclear organizer (15, 16, 17). Recently, a
CTCF-binding sites database (CTCFBSDB) has been cre-
ated to characterize experimentally identified and compu-
tationally predicted CTCF-binding sites (18). Interestingly,
it has been demonstrated that BORIS, a CTCF-paralogue
normally present only in male germ cells, is overexpressed in
several lung cancer cell lines, and it seems to deregulate
CTCF-target genes (19). In the present study, we report a
novel finding on Rb2/p130 gene regulation in lung cancer.
We have disclosed the mechanisms and "players" control-
ling Rb2/p130 gene expression in normal lung cells, char-
acterizing the alterations impairing Rb2/p130 expression in
NSCL and SCLC cells. We found that CTCF directly
regulates Rb2/p130 gene expression in MRC-5 lung fibro-
blasts, and that in both NSCLC and SCLC cell lines, which
exhibit increased and reduced levels of Rb2/p130, respec-
tively, the function of CTCF in regulating Rb2/p130 gene
expression is impaired. Importantly, our findings support
the hypothesis that the activity of CTCF in regulating Rb2/
p130 could be disturbed by binding of BORIS to Rb2/p130
in NSCLC and SCLC. In fact, the analysis of Rb2/p130
gene occupancy, using specific primers spanning a region of
the Rb2/p130 gene containing two putative CTCF/BORIS
binding sites, revealed that while this region is bound only
by CTCF in MRC-5 fibroblast cells, in NSCLC cell lines
the same region is bound by both CTCF and BORIS, and
in SCLC cells only by BORIS. Furthermore, we observed
that both CTCF and BORIS proteins are overexpressed in
SCLC and NSCLC cells with respect to the nonimmorta-
lized lung fibroblast cells MRC5, which express CTCF
only. We also found overexpression of both CTCF and
BORIS in the immortalized lung fibroblast cells NL-20.
Taken together, our results show that CTCF directly
controls Rb2/p130 gene expression in lung fibroblasts. We
believe that the binding of CTCF to Rb2/p130 induces,
and/or maintains, a specific local chromatin organization,
which in turn may govern the transcriptional activity of this
gene. However, in lung cancer cells the activity of CTCF in
controlling Rb2/p130 gene expression appears to be
impaired by BORIS binding to the Rb2/p130 gene, which
in turn could trigger changes in the chromatin asset estab-
lished by CTCF, then affecting the regulation of Rb2/p130
transcription.
Materials and Methods
Cell culture
The following cell lines were used: A549 and H358
(NSCLC), H82 and H69 (SCLC), and MRC-5 (normal
lung fibroblasts). The cell lines were purchased from Amer-
ican Type Culture Collection (ATCC) and cultured accord-
ing to the manufacturer's protocols.
Western blot analysis
Cells were trypsinized, washed in PBS and resuspended in
lysis buffer (50mMTris-Cl pH7.4, 5 mMEDTA, 250mM
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NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1 mM
Na3VO4) with fresh EDTA-free complete protease inhibi-
tor cocktail (ROCHE). After incubation in ice, lysates were
centrifuged (13,000  g, 15 minutes) and supernatants
were collected.
Protein concentrations were determined using Bio-Rad
Protein Assay (Bio-Rad). Total lysates were resolved by SDS-
polyacrylamide electrophoresis and then transferred to nitro-
cellulose membranes. Themembranes were probed for Rb2/
p130 (sc-317, Santa Cruz), CTCF (sc-28198, Santa Cruz),
or BORIS (sc-51038, Santa Cruz). The expression ofHSP70
and Actin protein was assessed to normalize protein loading.
Antibody binding was detected by incubation with horse-
radish peroxidase-coniugated secondary antibodies followed
by chemiluminescence (ECL Plus, Amersham Biosciences),
and visualized by exposing the membrane to X-ray films.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (XChIP) assays were
performed using the ChIP-IT Express Enzymatic kit (Active
Motif). For each immunoprecipitation, 10 mg of sheared
chromatin were incubated overnight with 2 mg of polyclonal
antibody specific for CTCF (Millipore, DAM1421463),
BORIS (Rockland, 600–401-907) or normal rabbit IgG
(Santa Cruz, sc-2027). PCR were performed on 1/10 of
immunoprecipitated DNA using specific primers for Rb2/
p130 core promoter region (Fig. 1A and B). As positive
control for CTCF and CTCFL/BORIS DNA-protein bind-
ing, PCR were performed amplyfing the H19/DMR locus
(20). Input represents the 0.25% of total pre-immunopre-
cipitated chromatin. The results were confirmed by three
independent experiments.
Transfection and reporter gene assay
Rb2/p130 Plasmids r1, r12, r123 and r23 were generated
by PCR-amplification of different regions of RBL2 pro-
moter, by digestion with BglII and HindIII and by cloning
into pGL3 basic (Promega) vector. The following primers
have been used: agatctgtttaaaatgcggggaaggt and gcccaagcttc-
cattcaaacggcgaagc (r1), agatctgtttaaaatgcggggaaggt and cggta-
agcttactggtcacctcccgacg (r12), agatctgtttaaaatgcggggaaggt and
aagcttgctggatctgaggggtg (r123), ggcagatctgcttcgccgtttgaatgg and
aagcttgctggatctgaggggtg (r23). Plasmids r123D1 and r123D2
were generated by site-directed mutagenesis with the
QuickChange II site-directed Mutagenesis Kit (Stratagene),
following manufacturer's instructions. r123 plasmid was
used as template and primers used were gcggggaaggtgcttt-
tatttgaaactaggggagc and gctcccctagtttcaaataaaagcaccttccccgc
(r123D1), ggaggaggaggacgacaagacgccgcgccgcctgc and gcaggc-
ggcgcggcgtcttgtcgtcctcctcctcc (r123D2). Plasmid CMV-CTCF,
containing the complete cDNA of CTCF, was generated by
digestion of pOTB7/CTCF with EcoRI and XhoI and
ligation with pCI-neo (Promega) digested with EcoRI
and SalI. Plasmid CMV-BORIS, containing the complete
cDNA of CTCFL/BORIS, was generated by digestion of
pCR4-TOPO/BORIS with EcoRI and ligation with pCI-
neo (Promega) digested with EcoRI. All plasmid constructs
were checked by DNA sequencing. The expression of
proteins following transient transfection was confirmed
by Western blot analysis. Dual luciferase reporter assay
−134 −115
A
B
C
TSS putative CTCF binding
forward ChlP primer
forward ChlP primer
Forward primer
cagcccgtgctcaagactac ccattcaaacggcgaagc 4 mM 52 °C 106
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Figure 1. A, schematic representation of Rb2/p130 gene region containing CTCF putative binding sites. B, nucleotide sequence of the primers spanning
theRb2/p130 region investigated.C, in vivobinding (XChIP)ofCTCFandBoris toRb2/p130 (RBL2/P130) promoter inMRC-5 lung fibroblasts, andH358 (NCSCL)
and H69 (SCLC)lung cancer cell lines. The XChIPs were performed using the ChIP-IT Express Enzymatic kit (Active Motif). For each immunoprecipitation,
10 mg of sheared chromatin was incubated overnight with 2 mg of polyclonal antibody specific for CTCF (Millipore, DAM1421463), BORIS (Rockland, 600–401-
907) or normal rabbit IgG (Santa Cruz, sc-2027). PCR was then performed on 1/10 of immunoprecipitated DNA using specific primers for Rb2/p130
core promoter region (B). As positive control for CTCF and BORIS DNA–protein binding, PCR was performed amplyfing the H19/DMR locus (Nguyen, 2008;
ref. 21). Input represents the 0.25% of total preimmunoprecipitated chromatin. The results were confirmed by three independent experiments.
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(Promega) was used to measure the firefly luciferase and
renilla luciferase activity within the transfected cells. pRL-
TK renilla luciferase vector was used in each transfection as
internal control of transfection efficiency in a ratio 1:20
respect to firefly luciferase vector. Each experiments was
conducted as suggested by the manufacturer. Luciferase
assays were performed with Sirius Luminometer (Berthold
detection systems). Relative light units (RLU) of firefly
luciferase activity was normalized against that of the renilla
luciferase, and this ration was set to 1 for the control (basal
activity of each promoter). Results represent the average of
at least three separate biological experiments  standard
error.
PCR nucleosome mapping
Nuclei were isolated from MRC-5, H69 and H358 cells
using a modified protocol of ChIP-IT Express Enzymatic
kit (Active Motif). Briefly, cells were grown to 70%–80%
confluence and fixed 50-100 with formaldehyde 1%. The
fixation reaction was stopped by adding glycine 0.125 M in
PBS to each of the plates for 50. Cellular pellets were
resuspended in 1 mL of lysis buffer supplemented with
PMSF and PIC (Active motif) and incubated for 300 at 4C
in constant agitation. The lysate was centrifuged at 2,400 g
for 100 at 4C and the pellet obtained was resuspended again
in 1 mL of lysis buffer. The lysate was transfered in an ice-
cold homogenizer and 10 strokes of tight pestle were applied.
The lysate was centrifuged again at 2,400 g for 100 at 4C
to obtain pelleted nuclei. Nuclei were resuspended and
incubated for 200 in ice in 96 mL of Microccal Nuclease
(MNase) buffer (Tris-Cl pH 7.5 10.4 mM, NaCl 10.4 mM,
MgCl2 3.01 mM, CaCl2 1.04 mM, NP-40 4.02%) supple-
mented with PMSF and PIC. After an initial incubation for
50 at 37C, 4 mL of MNase sigma (2 U, 0.5 U/mL) were
added and nuclei were incubated for 100 at 37C. MNase
reaction was stopped incubating each sample in ice after
adding EDTA 10mM. Protocol was continued following kit
instructions for the elution of sheared chromatin. The
mononucleosomal DNA fraction was gel extracted using
the Gel band extraction kit (QIAGEN), and 10 ng was used
as a template in each PCR. Undigested genomic DNA was
used as the positive control. No template was added to the
PCR negative control. Primer pairs were designed to amplify
areas of 80 to 120 bp on the Rb2/p130 promoter. Each PCR
product overlaps the neighboring amplified regions by
approximately 20 to 40 bp.
Results
Rb2/p130, CTCF, and BORIS expression in NSCLC
and SCLC cells
To study the protein expression pattern of Rb2/p130,
CTCF and BORIS in lung cancer we performed Western
blotting analyses in cycling NSCLC (A549 and H358)
and SCLC (H82 and H69) cell lines and in MRC-5 lung
fibroblasts. Interestingly, we observed low levels of Rb2/
p130 in SCLC cells, whereas in NSCLC Rb2/p130 was
significantly overexpressed with respect to the nonimmor-
talized lung fibroblast cells MRC-5 (Fig. 2A). Overexpres-
sion of CTCF and BORIS proteins was observed in both
SCLC and NSCLC cells with respect to the nonimmor-
talized lung fibroblast cells MRC-5, which expressed
CTCF only (Fig. 2A and B). The expression of HSP70
and b-Actin protein was assessed to normalize protein
loading.
Ectopic overexpression of BORIS and its effect on
CTCF and Rb2/p130 protein expression in MRC-5
lung fibroblasts
Plasmid CMV-BORIS, containing the complete cDNA
of BORIS, was generated by digestion of pCR4-TOPO/
BORIS with EcoRI and ligation with pCI-neo (Promega)
digested with EcoRI. Ectopic overexpression of BORIS
in MRC-5, which physiologically expresses CTCF
only, induced a significant decrease in Rb2/p130 protein
level whereas CTCF expression was only slightly altered
(Fig. 3).
X-ChIP revealed that CTCF binds to Rb2/p130 in lung
fibroblasts, the ability of CTCF to bind Rb2/p130 is lost
and acquired by BORIS in SCLC cells, and both
BORIS and CTCF bind to Rb2/p130 in NSCLC cells
We performed crosslinking chromatin immunoprecipita-
tion assays (XChIP) to investigate Rb2/p130 promoter
occupancy by CTCF and BORIS in MRC-5 lung fibro-
blasts, H358 and A549 (NSCLC), and in H82 and H69
(SCLC) cells. Our analysis was focused on the intergenic
region of Rb2/p130 between the nucleotides –155 and
þ159 containing two putative CTCF/BORIS binding sites
(ref. 21; Fig. 1A and B). XChIP assays were performed using
the ChIP-IT Express Enzymatic kit (Active Motif) as
NSCLC
A
B
MRC-5 A549 H358 H82 H69
MRC-5 A549 H358 H82 H69
- CTCF
- RBL2/p130
- HSP70
- BORIS
- Actin
SCLC
NSCLC SCLC
Figure 2. Protein expression level of (A) CTCF, and Rb2/p130 (RBL2/
p130), and (B) BORIS, in nonimmortalized lung fibroblast (MRC-5), in A549
and H358 (NSCLC), and in H82 and H69 (SCLC) cells. The relative protein
levels were detected by Western blotting using whole lysate. The
expression of HSP70 and Actin protein was assessed to normalize protein
loading.
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described in the Materials and Methods section. For each
immunoprecipitation, 10 mg of sheared chromatin was
incubated overnight with 2 mg of polyclonal antibody
specific for CTCF, BORIS (Rockland, 600–401-907) or
normal rabbit IgG. PCRs were performed on 1/10 of
immunoprecipitated DNA using specific primers for
Rb2/p130 core promoter region (Fig. 1B). As a positive
control for CTCF and CTCFL/BORIS DNA-protein bind-
ing, PCR was performed by amplyfying the H19/DMR
locus (20). Input represented the 0.25% of total pre-
immunoprecipitated chromatin. The results were con-
firmed by three independent experiments.
Importantly, the results from these experiments revealed a
different pattern of binding of CTCF and BORIS to Rb2/
p130 in MRC-5 fibroblasts, NSCLC and SCLC. As shown
in Figure 3C, we found that Rb2/p130 is bound (a)
exclusively by CTCF in MRC-5 fibroblast cells, (b) by
both CTCF and BORIS in H358 and A549 NSCLC cell
lines, and (c) exclusively by BORIS in H82 and H69 SCLC
cell lines (Fig. 1C). Our idea is that the differential binding
of CTCF and BORIS to Rb2/p130 may affect the tran-
scription of this gene.
Interestingly, silencing of CTCF by siRNA did not affect
BORIS expression whereas it induced a significant decrease
in both Rb2/p130 transcript and protein level, indicating a
key role for CTCF in controlling Rb2/p130 expression (data
not shown). Physiologically, the expression of CTCF and
BORIS could be controlled by independent mechanisms.
During the neoplastic process, events altering the mechan-
isms controlling CTCF and BORIS expression may induce
a "forced aberrant increase" in both CTCF and BORIS
protein levels triggering changes in the binding affinity of
these proteins to Rb2/p130 gene that in turn may differ-
entially affect the expression of Rb2/p130 gene in nonsmall
and small lung cancer cells.
CTCF controls Rb2/p130 gene expression in MRC-5
lung fibroblasts, and its regulatory function is impaired
in lung cancer cells
We evaluated the effect of ectopic expression of CTCF
and BORIS on Rb2/p130 gene expression in MRC-5 lung
fibroblasts, and in H358 (NSCLC) and H69 (SCLC) lung
cancer cell lines. We traced changes in the Rb2/p130
promoter activity by luciferase assay. Several Rb2/p130
plasmid constructs were generated and cotransfected with
CTCF or BORIS. As shown in Figure 4A, r123 construct
was designed to contain the Rb2/p130 gene region from
–155 to þ259, and contains two putative CTCF binding
sites (–134 to –115; þ198 to þ217). r1 and r12 constructs
were designed to contain only one CTCF binding site
(–134 to –115) and the Rb2/p130 gene region from
–155 to þ57 and þ142, respectively. r123D1 construct
contained the Rb2/p130 gene region from –155 to þ259,
but the CTCF binding site located between 125 to116
was mutated. r123D4 construct contained Rb2/p130 gene
region from 155 to þ259, but the CTCF binding site
located betweenþ198 toþ217 was mutated. r23 construct
contained the Rb2/p130 gene region from þ49 to þ 259,
but contained only the CTCF binding site located between
þ198 to 217. As shown in Figure 1B, the cotransfection of
CTCF and r123 construct increased Rb2/p130 promoter
activity about 3.4-fold 48 hours after transfection and only
in MRC-5 fibroblasts cells, indicating that the regulatory
function of CTCF on Rb2/p130 expression must be
impaired in both H358 and H69 cells. On the other hand,
cotransfection of BORIS and r123 construct induced an
increase in Rb2/p130 promoter activity 1.9-fold 48 hours
after transfection, and only in MRC-5.
Moreover, cotransfection of BORIS or CTCF and
r123D4 constructs induced a slight increase in Rb2/p130
promoter activity (1.2–1.7-fold), while cotransfection of
BORIS or CTCF and r123D1 induced a slight decrease
(0.5–0.8-fold) in all cell lines investigated. Interestingly,
deletion of the region between -155 to þ40 (construct r23)
had a significant effect on Rb2/p130 expression inducing a
tremendous increase in Rb2/p130 promoter activity in
response to both CTCF and BORIS transfection, and in
all the cell lines investigated (Fig. 4A and B), suggesting that
the Rb2/p130 region between 155 to þ40 contains
important elements for the regulatory activity of CTCF
and BORIS.
Importantly, the increase in CTCF and BORIS protein
levels after ectopic expression of CTCF and Boris was
detected in all cell lines investigated, even when no change
in Rb2/p130 promoter activity was observed, confirming the
reliability of the obtained evidence.
Determination of nucleosome positioning on Rb2/p130
promoter and 50-coding regions
To disclose the mechanisms responsible for the aberrant
Rb2/p130 expression in NSCLC and SCLC we performed
both genetic and epigenetic studies. Mutational analysis
did not show Rb2/p130 gene mutation in almost all the
NSCLC and SCLC cell lines we investigated, supporting
- CTCF
no
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ns
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m
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- RBL2/p130
- BORIS
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Figure 3. Ectopic overexpression of Boris and its effect on CTCF and Rb2/
p130 protein expression in MRC-5 lung fibroblasts. MRC-5 lung
fibroblasts were transfected with CMV-BORIS plasmid. After 72 hours
from transfection the level of CTCF and RB2/p130 proteins were detected
by Western analysis. The expression of Actin protein was assessed to
normalize protein loading.
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the idea that Rb2/p130 mutation is a rare event in lung
cancer and importantly, other mechanisms, such as epi-
genetic mechanisms mediated by CTCF and BORIS,
must contribute to impairing its expression. It is our idea
that Rb2/p130 expression is physiologically controlled by
CTCF, which by binding to the Rb2/p130 gene induces
and/or maintains a specific local chromatin organization
that governs Rb2/p130 transcriptional activity. However,
in lung cancer cells the control of CTCF on Rb2/p130
expression might be impaired by BORIS binding to the
Rb2/p130 gene, which in turn could trigger changes in the
chromatin asset established by CTCF. To test our hypoth-
esis, and since nucleosome positioning is essential for
understanding mechanisms of gene expression regulation,
we performed nucleosome mapping on Rb2/p130 promo-
ter and 50-coding regions (600 to þ700) using a PCR-
based method (22), in MRC5 lung fibroblasts, and in
H358 (NSCLC) and H69 (SCLC) lung cancer cells
(Fig. 5).
Briefly, MRC-5, H69 and H358 nuclei were obtained
using a modified protocol of ChIP-IT Express Enzymatic
kit (Active Motif). Cells were grown to 70% to 80%
confluence and fixed 50 to 100 with formaldehyde 1%.
The fixation reaction was stopped by adding glycine 0.125
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Figure 4. Effect of CTCT and BORIS on Rb2/p130 promoter activity. A, Rb2/p130 Plasmids r1, r12, r123, and r23 were generated by PCR-amplification of
different regions of Rb2/p130 promoter, by digestion with BglII and HindIII and by cloning into pGL3 basic (Promega) vector. The following primers have been
used: agatctgtttaaaatgcggggaaggt and gcccaagcttccattcaaacggcgaagc (r1), agatctgtttaaaatgcggggaaggt and cggtaagcttactggtcacctcccgacg (r12),
agatctgtttaaaatgcggggaaggt and aagcttgctggatctgaggggtg (r123), ggcagatctgcttcgccgtttgaatgg, and aagcttgctggatctgaggggtg (r23). Plasmids r123D1 and
r123D2 were generated by site-directed mutagenesis with the QuickChange II site-directed Mutagenesis Kit (Stratagene), following manufacturer's
instructions. r123 plasmid was used as template and primers used were gcggggaaggtgcttttatttgaaactaggggagc and gctcccctagtttcaaataaaagcaccttccccgc
(r123D1), ggaggaggaggacgacaagacgccgcgccgcctgc and gcaggcggcgcggcgtcttgtcgtcctcctcctcc (r123D2). B, plasmid CMV-CTCF, containing the complete
cDNA of CTCF, was generated by digestion of pOTB7/CTCF with EcoRI and XhoI and ligation with pCI-neo (Promega) digested with EcoRI and SalI. Plasmid
CMV-BORIS, containing the complete cDNA of CTCFL/BORIS, was generated by digestion of pCR4-TOPO/BORIS with EcoRI and ligation with pCI-neo
(Promega) digested with EcoRI. All plasmid constructs were checked by DNA sequencing. The expression of proteins following transient transfection was
confirmed byWestern blot analysis. Dual luciferase reporter assay (Promega) was used to measure the firefly luciferase and renilla luciferase activity within the
transfected cells. pRL-TK renilla luciferase vector was used in each transfection as internal control of transfection efficiency in a ratio 1:20 respect to firefly
luciferase vector. Each experiments was conducted as suggested by the manufacturer. Luciferase assays were performed with Sirius Luminometer (Berthold
detection systems). Relative light units (RLU) of firefly luciferase acitiviy was normalized against that of the renilla luciferase, and this ration was set to 1 for the
control (basal activity of each promoter). Results represent the average of at least three separate biological experiments  standard error.
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M in PBS to each of the plates for 50. Cellular pellets were
resuspended in 1 mL of lysis buffer supplemented
with PMSF and PIC (Active motif) and incubated for
300 at 4C in constant agitation. The lysate was centrifuged
at 2,400  g for 100 at 4C and the pellet obtained was
resuspended again in 1 mL of lysis buffer. The lysate was
transferred into an ice-cold homogenizer and 10 strokes of
tight pestle were applied. The lysate was centrifuged again at
2,400  g for 100 at 4C to obtain pelleted nuclei. Nuclei
were resuspended and incubated for 200 in ice in 96 mL
Microccocal Nuclease (MNase) buffer (Tris-Cl pH 7.5
10.4 mM, NaCl 10.4 mM, MgCl2 3.01 mM, CaCl2
1.04 mM, NP-40 4.02%) supplemented with PMSF and
PIC. After an initial incubation for 50 at 37C, 4 mL of
MNase (2 U, 0.5 U/mL) were added and nuclei were
incubated for 100 at 37C. MNase reaction was stopped
incubating each sample in ice after adding EDTA 10 mM.
Protocol was continued following kit instructions for the
elution of sheared chromatin. The mononucleosomal DNA
fraction was gel extracted using the Gel band extraction kit
(QIAGEN), and 10 ng was used as a template in each PCR.
Undigested genomic DNA was used as the positive control.
No template was added to the PCR negative control. In
order to deal with the different amplification efficiencies of
the primer sets, each was extensively and independently
characterized to determine appropriate cycle numbers. Pri-
mer pairs were designed to amplify areas of 80 to 120 bp on
the Rb2/p130 promoter. Each PCR product overlapped
the neighboring amplified regions by approximately 20–40
bp. The PCR products were numbered, and the regions
Figure 5. Determination of
nucleosome positioning on the
human Rb2/p130 promoter and
50-coding regions in MRC-5,
H358, and H69 cell lines. (A)
Illustration of the Rb2/p130
promoter and 50-coding regions.
The amplified region of each PCR
product is shown with its
corresponding number. The
resulting nucleosomal regions are
diagrammed as solid black bars.
(B) Results of PCR analyses with
the number corresponding to the
amplified PCR product listed in
Table 1. Samples were from
formaldehyde cross-linked
chromatin that either was not
digested with micrococcal
nuclease (undigested chromatin,
500 ng) or was subjected to
micrococcal nuclease digestion to
produce mononucleome-size
chromatin (digested chromatin,
500 ng). Nuclease-free water
without template was used as
negative control.
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amplified were as follows: 1, 521 to 426; 2, 446 to
342; 3, 364 to 265; 4, 285 to 182; 5, 243 to
135; 6, 155 to 36; 7, 40 to þ66; 8, þ48 to þ140;
9, þ124 to þ259; 10, þ183 to þ264; 11, þ241 to þ354;
12,þ331 toþ405; 13,þ388 toþ502; 14,þ471 toþ593;
15, þ578 to þ699 (Fig. 5).
We observed interesting variations in the positioning of
nucleosomes on Rb2/p130 promoter and 50-coding regions
between H69 (SCLC) and H358 (NSCLC) lung cancer cell
lines, as well as between H69 and H358 cells and MRC-5
lung fibroblasts, which greatly supports our idea that the
binding of CTCF and/or BORIS to the Rb2/p130 gene
leads to changes in the local chromatin organization affect-
ing Rb2/p130 transcriptional activity. Nucleosome-free
regions were centered at about position 4, 6, 7, 11, 14
and 15 inMRC5 lung fibroblasts, at about position 4, 6 and
11 in H358 (NSCLC) cells, and at about position 3, 4, 5, 6,
7, 11, 14 and 15 in H69 (SCLC) cells (Fig. 5).
Currently, we are further investigating the phenomena
observed, and also determining the relative levels of histone
H3 andH4 acetylation on the single nucleosomes identified.
Discussion
Until now, the contribution of Rb2/p130-retinoblastoma
related protein to lung tumorigenesis remains controversial
and under debate. However, our previous studies regarding
Rb2/p130 in lung cancer have suggested that Rb2/p130
epigenetic modifications, and/or post-translation modifica-
tion, rather than Rb2/p130 genetic alterations, might con-
tribute to impairing Rb2/p130 activity during the
neoplastic process.
Here, we report a novel finding on Rb2/p130 gene
regulation in lung cancer by disclosing the mechanisms
and the "players" that directly control Rb2/p130 gene
expression in normal lung cells, and by characterizing the
events responsible for the deregulated expression of Rb2/
p130 gene in NSCL and SCLC cells. Specifically, our
studies indicate that the chromatin insulator CCCTC-
binding factor (CTCF) binds to the Rb2/p130 gene and
controls its expression in normal lung fibroblasts. However,
during the neoplastic process defects occurring in the
mechanisms by which CTCF controls Rb2/p130 gene
expression seem to trigger the binding of BORIS (CTCF-
paralogue) to the Rb2/p130 gene in nonsmall (NSCLC) and
small (SCLC) lung cancer cells. It is our idea that the
binding of BORIS to Rb2/p130 affects the transcription of
this gene by altering the chromatin asset established by
CTCF through mechanisms that involve changes in nucleo-
some positioning.
Importantly, the activities of CTCF and BORIS in
controlling Rb2/p130 gene expression could specifically rely
on specific alterations in p16INK4a/CyCD1/RB1, p14
ARF/mdm2/p53, and PI3K/AKT signaling, as well as on
the presence of alterations in the other Rb family members,
in nonsmall and small cell lung cancer, which in turn may
critically influence Rb2/p130 functions in suppressing
epithelial cell growth.
These studies provide essential basic insights into the
mechanisms that control Rb2/p130 gene expression in lung
cancer, offering a potential paradigm for the actions of other
activators and/or corepressors, such as CTCF and BORIS,
that could be crucial in explaining how alterations in the
mechanisms regulating Rb2/p130 gene expression may
accelerate the progression of lung tumor, or favor the onset
of recurrences after cancer treatment, perhaps by affecting
the apoptosis and senescence signaling that are Rb2/p130-
dependent.
The characterization of the mechanisms regulating
Rb2/p130 gene expression, and the identification of the
Table 1. Amplified PCR product
Region amplified Forward primer Reverse primer PCR Magnesium
concentration
PCR Annealing
temperature
Amplicon
length (bp)
1 ggaaaggactgttacaatctttg tgcccttgttcattcctggg 1.8mM 52C 95
2 cccaggaatgaacaagggca gcctttgcaaaaatcctaacagt 1.8mM 54C 105
3 actgttaggatttttgcaaaggc ttcctcatcgcctggatatc 3mM 56C 99
4 gatatccaggcgatgaggaa caacagggctgtactgacga 3mM 56C 104
5 ggatacgaaaccttcacacgtc accttccccgcattttaaac 3mM 52C 108
6 gtttaaaatgcggggaaggt ggdgctgggaaacgtagt 1.8mM 56C 120
7 cagcccgtgctcaagactac ccattcaaacggcgaagc 3mM 52C 106
8 gcttcgccgtttgaatgg actggtcacctcccgacg 3mM 55C 93
9 cgtcgggaggtgaccagt tgctggatctgaggggtg 1.8mM 55C 136
10 atgaggaggaggaggacgac aaccgctgctggattctgagg 1.8mM 56C 81
11 cacccctcagatccagca agcgtgtagctttcgctcat 3mM 55C 115
12 cagcatgagcgaaagctacac ggttcacgccaactaggc 3mM 52C 75
13 gcctagttggcgtgaacc ggaatagcgcagaggaagtc 1.8mM 52C 114
14 gagaggggtggggacttcct gtgctactttagggcaagacg 3mM 57C 123
15 tgccctaaagtagcacagcaa ttgacaacgacactagttcattc 3mM 55C 121
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alterations that affect this regulation (as well as the biological
effect) in lung cancer offer the opportunity to disclose the
distinct role played by Rb2/p130 in executing its onco-
suppressive functions when anti-proliferative Rb1- and
p53- mediated signaling is impaired. Insights into the
molecular pathways that are strictly correlated to Rb2/
p130 expression and constitutively active in NSCLC and
SCLC cells may provide new biomarkers for an early
diagnosis of lung cancer and/or predictive factors to deter-
mine the effect on tumor treatment, as well as may lead to
the development of novel therapies based upon clinical
modulation of Rb2/p130, CTCF and/or BORIS expres-
sion. We are currently investigating the "molecular signa-
tures" underlying the NSCLC and SCLC phenotype
through an integrated survey of the changes in gene expres-
sion profiles, Rb2/p130-dependent and-independent, that
occur in NSCLC and SCLC during the evolution of this
disease, with the goal of understanding the relationship
between these changes and the proliferative and metastatic
potential of lung cancer cells.
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Correction
Correction: CTCFandBORISRegulateRb2/p130
Gene Transcription: A Novel Mechanism and a
New Paradigm for Understanding the Biology of
Lung Cancer
In this article (Mol Cancer Res 2011;9:225–233), which appeared in the
February 2011 issue of Molecular Cancer Research (1), the support of the study
by AIRC—Associazione Italiana per la Ricerca sul Cancro (IG 2010–10457 to
Antonio Giordano) was not acknowledged. The online version of this article has
been corrected and no longer matches the print version. The authors regret the
omission.
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